-$1.19 EPS Expected for Catalyst Biosciences Inc (NASDAQ:CBIO) This Quarter

Wall Street analysts forecast that Catalyst Biosciences Inc (NASDAQ:CBIO) will post ($1.19) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings of ($0.64) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 85.9%. The business is scheduled to announce its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Catalyst Biosciences will report full-year earnings of ($4.74) per share for the current financial year, with EPS estimates ranging from ($4.83) to ($4.64). For the next fiscal year, analysts forecast that the business will report earnings of ($4.05) per share, with EPS estimates ranging from ($4.54) to ($3.55). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.01.

A number of equities analysts have recently issued reports on CBIO shares. ValuEngine upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Chardan Capital set a $25.00 target price on shares of Catalyst Biosciences and gave the stock a “buy” rating in a research report on Sunday, August 25th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $20.38.

Shares of CBIO traded down $0.07 during mid-day trading on Friday, reaching $5.22. 122,460 shares of the company’s stock were exchanged, compared to its average volume of 194,730. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.83 and a quick ratio of 15.83. The stock has a market capitalization of $62.74 million, a PE ratio of -1.95 and a beta of 2.14. The business’s fifty day simple moving average is $5.98 and its 200-day simple moving average is $7.65. Catalyst Biosciences has a 52-week low of $4.52 and a 52-week high of $11.44.

Large investors have recently bought and sold shares of the stock. Private Advisors LLC grew its stake in shares of Catalyst Biosciences by 5.9% during the first quarter. Private Advisors LLC now owns 26,994 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 1,500 shares during the period. A.R.T. Advisors LLC grew its position in Catalyst Biosciences by 16.0% during the 2nd quarter. A.R.T. Advisors LLC now owns 22,828 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 3,150 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Catalyst Biosciences by 2,288.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,037 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 3,868 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in Catalyst Biosciences during the 2nd quarter worth approximately $38,000. Finally, Jane Street Group LLC purchased a new stake in Catalyst Biosciences during the 2nd quarter worth approximately $107,000. Hedge funds and other institutional investors own 62.60% of the company’s stock.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Recommended Story: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.